Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 19/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | HTR7 | P34969 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5785029 | 0.92 | HTR6 (0.84) | HTR6POLB | |
| Hydrochloric Acid SCHEMBL5786408 | 0.90 | HTR6 (0.82) | HTR6POLB | |
| SCHEMBL3895154 | 0.84 | HTR6 (0.72) | HTR6HTR2AHTR2CHTR7 | |
| SCHEMBL3885076 | 0.84 | HTR6 (0.72) | HTR6HTR2AHTR2CHTR7 | |
| SCHEMBL5788602 | 0.84 | HTR6 (1.00) | HTR6HTR2AHTR2CHTR7 | |
| SCHEMBL5783671 | 0.82 | HTR6 (0.70) | HTR6HTR2AHTR2CHTR7 | |
| SCHEMBL5785272 | 0.82 | HTR6 (0.71) | HTR6HTR2AHTR2CHTR7 | |
| SCHEMBL5788313 | 0.81 | HTR6 (0.69) | HTR6 | |
| SCHEMBL5782859 | 0.81 | HTR6 (0.67) | HTR6 | |
| Hydrochloric Acid SCHEMBL5785364 | 0.81 | HTR6 (0.97) | HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1509501-B1 | 1-(AMINOALKYL)-3-SULFONYLINDOLE AND -INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH CORP (US) | 2006-12-20 | — | — | EP | claimed |
| EP-1509501-A1 | 1-(AMINOALKYL)-3-SULFONYLINDOLE AND -INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | Wyeth (US) | 2005-03-02 | — | — | EP | claimed |
| US-6727246-B2 | ENHANCEMENT OF COGNITION AND MEMORY IN HUMAN DISEASES SUCH AS ALZHEIMER'S | WYETH | 2004-04-27 | — | — | US | claimed |
| US-20030232828-A1 | 1-(AMINOALKYL)-3-SULFONYLINDOLE AND-INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH | 2003-12-18 | — | — | US | claimed |
| WO-2003101962-A1 | 1-(AMINOALKYL)-3-SULFONYLINDOLE AND -INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2003-12-11 | — | — | WO | claimed |
| EP-1509501-B1 | 1-(AMINOALKYL)-3-SULFONYLINDOLE AND -INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH CORP (US) | 2006-12-20 | — | — | EP | disclosed |
| EP-1509501-A1 | 1-(AMINOALKYL)-3-SULFONYLINDOLE AND -INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | Wyeth (US) | 2005-03-02 | — | — | EP | disclosed |
| US-6727246-B2 | ENHANCEMENT OF COGNITION AND MEMORY IN HUMAN DISEASES SUCH AS ALZHEIMER'S | WYETH | 2004-04-27 | — | — | US | disclosed |
| US-20030232828-A1 | 1-(AMINOALKYL)-3-SULFONYLINDOLE AND-INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH | 2003-12-18 | — | — | US | disclosed |
| WO-2003101962-A1 | 1-(AMINOALKYL)-3-SULFONYLINDOLE AND -INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232828-A1 | 1-(AMINOALKYL)-3-SULFONYLINDOLE AND-INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | HTR6, HTR3A, HTR5A | HTR6 1/4885POLB 4868/4885HTR2A 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.